Table 2 Description of G-CSF use and occurrence of neutropenic events in study sample (breast cancer and NHL patients)
Breast cancer regimens | NHL regimens | ||||
|---|---|---|---|---|---|
Outcome | FEC (n = 73) | FEC-T (n = 60) | All (n = 161) | Dose-dense (n = 11) | All (n = 39) |
Patients with G-CSF use | n (%) | n (%) | n (%) | n (%) | n (%) |
Primary prophylaxis (PP) | 0 | 1 (2) | 1 (<1) | 3 (27) | 10 (26) |
Secondary prophylaxis (SP) | 36 (49) | 23 (38) | 67 (42) | 7 (64) | 16 (41) |
due to FN (SP-FN) | 23 (32) | 17 (28) | 47 (29) | 6 (55) | 13 (33) |
Total patients developing FN a | 23 (32) | 19 (32) | 50 (31) | 7 (64) | 16 (41) |
Cycle # to start SP b | Mean cycle # | Mean cycle # | Mean cycle # | Mean cycle # | Mean cycle # |
After FN | 3.2 | 3.4 | 3.4 | 2.5 | 2.7 |
After PSN | 2.1 | 2 | 2.1 | 2.0 | 2.0 |
Total number of cycles observed | 424 | 402 | 969 | 49 | 208 |
Cycles protected by G-CSF (% observed cycles) | 145 (34) | 103 (26) | 287 (30) | 36 (73) | 114 (55) |
Neutropenic events by presence of PP/SP | |||||
N patients with at least one unprotected cycle | 73 | 59 | 160 | 8 | 29 |
N (%) patients with event in unprotected cycles (first event only) | 36 (49) | 25 (42) | 70 (44) | 7 (88) | 17 (58) |
Of which FN | 23 (32) | 19 (32) | 50 (31) | 6 (75) | 14 (48) |
N patients with at least one protected cycle | 36 | 24 | 68 | 10 | 26 |
N (%) patients with event in protected cycles | 2 (6) | 0 | 3 (4) | 1 (10) | 8 (31) |
after PP | NA | 0 | 0 | 1 (10) | 2 (8) |
after SP | 2 (6) | 0 | 3 (4) | 0 | 6 (23) |
Impact of FN on chemotherapy delivery (N patients and % among those who developed FN) | |||||
Dose adjustment | 4 (17) | 4 (21) | 12 (24) | 0 | 0 |
Dose delay | 5 (22) | 3 (16) | 12 (24) | 3 (43) | 6 (38) |
At least 1 cycle dropped | 2 (9) | 5 (26) | 8 (16) | 0 | 0 |
Switch chemotherapy protocol | 3 (13) | 2 (11) | 6 (12) | 0 | 0 |
Any type | 8 (35) | 8 (42) | 20 (40) | 3 (43) | 6 (38) |